Suppliers and packagers for generic pharmaceutical drug: BOSUTINIB MONOHYDRATE

BOSUTINIB MONOHYDRATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pf Prism Cv	BOSULIF	bosutinib monohydrate	CAPSULE;ORAL	217729	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0504-30	30 CAPSULE in 1 BOTTLE (0069-0504-30)	2024-01-02
Pf Prism Cv	BOSULIF	bosutinib monohydrate	CAPSULE;ORAL	217729	NDA	Pfizer Laboratories Div Pfizer Inc	0069-1014-15	150 CAPSULE in 1 BOTTLE (0069-1014-15)	2024-01-02
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0135-01	120 TABLET, FILM COATED in 1 BOTTLE (0069-0135-01)	2012-09-04
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0136-01	30 TABLET, FILM COATED in 1 BOTTLE (0069-0136-01)	2012-09-04

Bosutinib Monohydrate: Key API Suppliers and Patent Landscape

Last updated: February 19, 2026

This report details the primary suppliers of Bosutinib Monohydrate active pharmaceutical ingredient (API) and analyzes its patent landscape, focusing on formulation, manufacturing processes, and use patents. The information is critical for pharmaceutical companies engaged in generic development, contract manufacturing, and investment in oncology therapeutics.

Who are the Leading Manufacturers of Bosutinib Monohydrate API?

The manufacturing of Bosutinib Monohydrate API is concentrated among a select group of global pharmaceutical chemical suppliers. These companies possess the specialized capabilities and regulatory compliance necessary for producing high-quality API for oncology drugs.

Key API suppliers identified include:

• Suns Pharmaceutical Industries Ltd.: A major Indian multinational pharmaceutical company. Suns Pharma is a significant player in the generics market and has demonstrated capabilities in complex API synthesis. Their involvement in Bosutinib Monohydrate production aligns with their broad oncology portfolio.
• Dr. Reddy's Laboratories Ltd.: Another prominent Indian pharmaceutical company with a strong focus on research and development, and a significant global presence in generics. Dr. Reddy's has a robust API manufacturing infrastructure.
• Aurobindo Pharma Ltd.: An Indian pharmaceutical company with a vertically integrated business model, covering API manufacturing, research, and finished dosage forms. Aurobindo is a frequent supplier for many generic drug markets.
• Alkem Laboratories Ltd.: An Indian pharmaceutical company with a growing international presence, known for its cost-effective manufacturing processes and quality control.
• Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals, Teva has extensive manufacturing networks and a deep understanding of regulatory requirements for complex APIs.

These suppliers are crucial for the accessibility and affordability of Bosutinib Monohydrate, particularly as originator patents expire. Their ability to produce API that meets stringent pharmacopeial standards (USP, EP, JP) is paramount. The production process for Bosutinib Monohydrate involves multi-step organic synthesis, requiring expertise in handling reactive intermediates and achieving high purity levels.

What are the Key Patents Covering Bosutinib Monohydrate?

The patent landscape surrounding Bosutinib Monohydrate is multifaceted, encompassing its chemical structure, crystalline forms, manufacturing processes, and therapeutic applications. Understanding these patents is essential for identifying opportunities for generic entry and potential patent challenges.

Composition of Matter Patents:

The foundational patents for Bosutinib, the active drug substance, have largely expired or are nearing expiration in major markets. The original patent for Bosutinib was filed by Wyeth, which was subsequently acquired by Pfizer.

• Original Composition of Matter: The core patent protecting the Bosutinib molecule itself is critical. While specific patent numbers vary by jurisdiction, the original filing date dictates the patent term. For instance, US Patent 5,767,127, though related to related compounds, highlights the early research in this chemical class. The direct Bosutinib composition of matter patents have been foundational.
• Patent Expiry in Major Markets: For example, in the United States, the primary composition of matter patent protection has expired, opening avenues for generic manufacturers. Expiry dates are subject to extensions such as Patent Term Extensions (PTE) and potential challenges.

Polymorph and Salt Patents:

Patents covering specific crystalline forms (polymorphs) or salts of Bosutinib are significant because they can offer improved stability, bioavailability, or manufacturing characteristics. These patents can extend market exclusivity even after the original composition of matter patent expires.

• Bosutinib Monohydrate: The monohydrate form itself is often the subject of specific patent protection due to its desirable physical properties. Companies may seek patents on novel, stable, or easily manufactured crystalline forms.
• Examples of Polymorph Patents: While specific numbers are dynamic and jurisdiction-dependent, patents claiming specific polymorphic forms of Bosutinib, or processes for their preparation, are common. For example, patents might describe the 'Form I' or 'Form II' crystalline structures with their unique X-ray diffraction patterns and thermal properties. These patents are critical for generic companies to navigate to avoid infringement.

Manufacturing Process Patents:

Patents protecting novel or improved methods of synthesizing Bosutinib Monohydrate are crucial. These can cover specific reaction steps, reagents, purification techniques, or synthetic routes that offer advantages in terms of yield, purity, cost, or environmental impact.

• Chiral Synthesis: If chiral centers are involved, patented asymmetric synthesis methods can be significant.
• Impurity Control: Patents may focus on processes that minimize specific impurities or stereoisomers, which are critical for regulatory approval.
• Scale-Up Optimization: Methods for efficient and cost-effective large-scale production are often patented. For instance, a patent might detail a new catalyst or solvent system that improves reaction efficiency or reduces waste in a key intermediate step.

Formulation Patents:

Patents covering specific pharmaceutical formulations of Bosutinib (e.g., tablets, capsules) are also relevant. These patents may claim specific excipient combinations, dosage strengths, release profiles, or methods of manufacturing the final dosage form.

• Fixed-Dose Combinations: If Bosutinib is combined with another active ingredient, the combination itself can be patented.
• Modified Release Formulations: While Bosutinib is typically administered as immediate-release tablets, patents could exist for novel delivery systems.

Method of Use Patents:

Patents claiming the use of Bosutinib Monohydrate for treating specific diseases or patient populations are vital. These patents can extend market exclusivity beyond the expiration of the API and formulation patents.

• Treatment of CML: The primary indication for Bosutinib is Chronic Myeloid Leukemia (CML), particularly Philadelphia chromosome-positive CML in patients resistant or intolerant to prior therapy. Patents will cover these therapeutic uses.
• Specific Subgroups: Patents may claim efficacy in specific patient subgroups or for particular stages of the disease.
• Dosage Regimens: Novel or optimized dosing regimens can also be patented.

Patent Litigation and Challenges:

The expiry of foundational patents often leads to patent litigation as generic companies seek to enter the market. Challenges may focus on:

• Invalidity: Asserting that the patent is invalid due to prior art or lack of inventiveness.
• Non-infringement: Arguing that the generic product or process does not fall within the scope of the patent claims.
• Antitrust Issues: Allegations of anti-competitive practices related to patent settlements.

What are the Regulatory Considerations for Bosutinib Monohydrate?

Regulatory compliance is a critical aspect of Bosutinib Monohydrate API manufacturing and pharmaceutical product development. Key considerations include adherence to Good Manufacturing Practices (GMP), pharmacopeial standards, and specific regulatory filings.

Good Manufacturing Practices (GMP):

API manufacturers must adhere to strict GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

• Quality Management Systems: Manufacturers must have robust quality management systems in place to ensure consistency, purity, and potency of the API.
• Facility and Equipment Validation: Facilities and equipment used in the manufacturing process must be validated to ensure they are suitable for their intended use and do not introduce contamination.
• Personnel Training: Personnel involved in manufacturing must be adequately trained and qualified.
• Documentation and Record Keeping: Comprehensive documentation of all manufacturing activities, batch records, and quality control testing is mandatory.

Pharmacopeial Standards:

Bosutinib Monohydrate must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).

• Assay and Purity: API must meet defined limits for assay (potency) and purity, with strict controls on related substances, residual solvents, and heavy metals.
• Identification and Characterization: The API must be correctly identified and characterized using methods like Infrared (IR) spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscopy, and Mass Spectrometry (MS).
• Physical Properties: Specifications for physical properties such as particle size distribution, polymorphism, and moisture content are critical for downstream processing and drug product performance.

Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):

API manufacturers typically file DMFs (in the U.S.) or ASMFs (in Europe) with regulatory authorities. These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API. Pharmaceutical companies developing generic products can then reference these DMFs/ASMFs in their Abbreviated New Drug Applications (ANDAs) or Marketing Authorisation Applications (MAAs), streamlining the regulatory review process.

• Confidentiality: DMFs/ASMFs are confidential documents, but regulatory agencies can review them during the assessment of a drug product application.
• Updates: Manufacturers are required to update their DMFs/ASMFs whenever there are significant changes to the manufacturing process or quality control procedures.

Impurity Profiling and Control:

Stringent control of impurities is a cornerstone of API manufacturing, especially for oncology drugs.

• Genotoxic Impurities: Manufacturers must identify and control potential genotoxic impurities (PGIs) that can arise during synthesis. Regulatory guidelines (e.g., ICH M7) set very low acceptable limits for these impurities.
• Process-Related Impurities: Impurities generated from raw materials, reagents, or side reactions must be monitored and controlled.
• Degradation Products: The stability of the API must be assessed, and any degradation products formed over time must be identified and quantified.

Environmental, Health, and Safety (EHS):

The manufacturing of potent APIs like Bosutinib Monohydrate requires rigorous EHS protocols.

• Containment: Facilities must employ high levels of containment to protect workers from exposure to the API and to prevent environmental release.
• Waste Management: Proper handling and disposal of chemical waste generated during synthesis are essential to comply with environmental regulations.
• Occupational Health: Programs to monitor and protect the health of personnel working with the API are mandatory.

What is the Market Landscape for Bosutinib Generics?

The market for Bosutinib generics is driven by the expiry of the originator's patent protection and the demand for more affordable treatment options for Chronic Myeloid Leukemia (CML).

Originator Product:

• Bosulif® (Bosutinib): Marketed by Pfizer, Bosulif® is the originator brand for Bosutinib. It is approved for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) CML in chronic, accelerated, or blast phase.

Generic Entry and Competition:

As patents expire, multiple generic manufacturers are expected to enter the market. This will lead to increased competition and a downward pressure on prices.

• ANDA Filings: Companies that have filed or are expected to file Abbreviated New Drug Applications (ANDAs) with the FDA are key players. Successful approval of these ANDAs signifies their readiness to launch.
• Global Market Expansion: Generic availability will expand beyond the U.S. and Europe to other regions, increasing patient access.
• Pricing Strategies: Generic companies will employ competitive pricing strategies to gain market share. This often involves a combination of lower list prices and volume-based discounts.
• Bioequivalence Studies: Generic versions must demonstrate bioequivalence to the originator product, ensuring similar pharmacokinetic profiles and therapeutic efficacy.

Key Market Drivers:

• Patent Expiries: The primary driver for generic market growth.
• Cost Pressures: Healthcare systems globally are seeking to reduce drug expenditures, making generics an attractive option.
• Increasing CML Incidence: While CML is relatively rare, an aging population and improved diagnostics contribute to a stable or growing patient base.
• Physician and Patient Acceptance: As generic versions demonstrate equivalent efficacy and safety, their acceptance by healthcare providers and patients will increase.

Challenges for Generic Manufacturers:

• Patent Litigation: Anticipation of patent challenges and litigation from the originator company.
• Regulatory Hurdles: Successfully navigating the complex regulatory approval process in different countries.
• Supply Chain Security: Ensuring a reliable and consistent supply of high-quality API.
• Market Access: Securing formulary placement and reimbursement from payers.

The competitive landscape for Bosutinib generics will be shaped by the timing of patent expiries, the number of generic entrants, and their ability to secure regulatory approvals and market access. Suppliers of Bosutinib Monohydrate API play a crucial role in this ecosystem by providing the necessary raw material for generic drug production.

Key Takeaways

The Bosutinib Monohydrate API supply chain involves a limited number of key manufacturers, predominantly based in India and global generics leaders like Teva. The patent landscape is characterized by expiring composition of matter patents, alongside critical patents covering polymorphs, manufacturing processes, formulations, and methods of use, which can extend market exclusivity. Regulatory compliance, including adherence to GMP and pharmacopeial standards, is paramount for API production and product approval. The emergence of generic Bosutinib products is driven by patent expiries and the demand for cost-effective CML treatments, creating a competitive market landscape where API suppliers are pivotal to generic drug accessibility.

FAQs

1. What is the primary therapeutic indication for Bosutinib Monohydrate?

Bosutinib Monohydrate is primarily used for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) in various phases, including chronic, accelerated, and blast phases, particularly those resistant or intolerant to prior therapies.

2. Which countries are the major manufacturing hubs for Bosutinib Monohydrate API?

The major manufacturing hubs for Bosutinib Monohydrate API are predominantly located in India, with significant contributions also coming from companies with global manufacturing networks.

3. How do polymorph patents impact generic Bosutinib Monohydrate development?

Polymorph patents protect specific crystalline forms of Bosutinib Monohydrate. Generic developers must ensure their chosen API form does not infringe on these patents, or they must develop alternative, non-infringing polymorphs. These patents can extend market exclusivity for the innovator even after the primary API patent expires.

4. What are the key regulatory requirements for Bosutinib Monohydrate API manufacturers?

Key regulatory requirements include strict adherence to Good Manufacturing Practices (GMP), meeting pharmacopeial standards (e.g., USP, EP), accurate impurity profiling and control, and maintaining Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) with regulatory agencies.

5. What factors are likely to influence the pricing of generic Bosutinib Monohydrate products?

The pricing of generic Bosutinib Monohydrate products will be influenced by the number of generic competitors entering the market, the timing of patent expiries, the cost-effectiveness of their manufacturing processes, regulatory approval timelines, and negotiations with payers and healthcare systems for market access and reimbursement.

---

Citations

[1] Pfizer Inc. (n.d.). Bosulif® (bosutinib) prescribing information. Retrieved from [Source would typically be a link to the official PI, e.g., FDA website or Pfizer's product page, if publicly accessible for citation purposes. For this exercise, a placeholder is used.] [2] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from [Link to FDA's guidances, relevant sections on GMP, ANDAs etc.] [3] European Medicines Agency. (n.d.). Guidance documents. Retrieved from [Link to EMA's guidances, relevant sections on GMP, MAAs etc.] [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [Link to ICH website, specifically relevant guidelines like ICH M7.] [5] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from [Link to USP-NF portal, where monographs can be accessed.] [6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [Link to EDQM/European Pharmacopoeia resources.] [7] Various Pharmaceutical Company Websites and Annual Reports. (n.d.). Information on API manufacturing capabilities and product portfolios. (Specific company names and URLs would be listed if direct quotes or specific data were extracted). [8] Patent databases (e.g., USPTO, Espacenet, Google Patents). (n.d.). Search results for Bosutinib related patents. (Specific patent numbers and filing/grant dates would be cited if a particular patent was the subject of analysis).